Andrew King, BVMS, Ph.D.

Dr. King is Jade Biosciences’ Chief Scientific Officer, Head of Research and Development and most recently served as a consultant to Paragon Therapeutics from May 2024 to July 2024 to help build and launch Jade Biosciences. From June 2021 to October 2023, Dr. King served as Chief Scientific Officer and, from May 2019 to June 2021, as Head of Renal Discovery and Translational Medicine at Chinook Therapeutics, Inc., a Nasdaq-listed biopharmaceutical company that was acquired by Novartis AG in August 2023, where he was responsible for overseeing the discovery research, non-clinical development, translational medicine and early clinical development teams, and played a lead role in late-stage clinical development strategy as chair or co-chair of the development review committee and as a sponsor representative on the company’s global Phase 3 clinical trial steering committees. 

From August 2018 through May 2019, Dr. King served as the Executive Vice President of Discovery at BIOAGE Labs, a private biotechnology company. From 2015 through August 2018, Dr. King served as the Senior Director of Discovery and Translational Biology at Ardelyx, Inc. (Nasdaq: ARDX), a biotechnology company, where he focused on delivering small molecule candidates for the treatment of cardio-renal, metabolic and gastrointestinal diseases and made contributions to the approval of XPHOZAH® and IBSRELA®, including elucidating their novel mechanisms of action. Prior to Ardelyx, Inc., Dr. King was a Principal Research Scientist at AbbVie Inc. (NYSE: ABBV), a biopharmaceutical company, from 2013 through 2015, where he led the Renal Discovery scientific strategy. From 2008 to 2012, Dr. King held positions of increasing responsibility at Abbott Laboratories (NYSE: ABT), a biotechnology company. 

Dr. King received a B.Sc. in Veterinary Biology from Murdoch University in Australia, a BVMS from Murdoch University in Australia and a Ph.D. in Pharmacology and Toxicology from Michigan State University.